

# Our Manifesto

## Introduction

Climate change, the problem of waste and other sustainability-related challenges make the fact inescapable: today's decisions significantly impact the prospects and choices of future generations. Worldwide, activities that aim to reduce environmental impact can ensure the achievement of the ambitions set out in the Paris Climate Agreement and United Nations Sustainable Development Goals and promote the transition to a regenerative and restorative economy.

The Alliance would like to contribute to these ambitions and aims to look ahead, taking responsibility for our actions today in order to be part of the solution for a sustainable future. The Alliance is a working group of likeminded companies, along the pharmaceutical supply chain with the shared goal of net zero greenhouse gas (GHG) emissions. Our main focus is significant GHG emissions reduction with the guidance of the GHG Protocol standards.

Delivering on the **common goal of net zero GHG emissions** (further referred to as net zero) will require companies like ours to transform our operations, products, services, logistics, innovation and investments. The Circular Economy principles of collaboration and joint responsibility over the entire supply chain will be the core values that enable a total net zero supply chain; they represent the fundamental values of this Alliance.

Our combined effort is also key to overcoming some of the toughest challenges, which include regulatory hurdles, bringing our smaller suppliers along with us and finding breakthrough technologies and solutions. We will activate new, viable and long-term business opportunities across sectors and geographies. In this way, we believe we can contribute to dismantling the systemic sustainability challenges facing the pharmaceutical industry.

## Our Vision

The Alliance strives for the transition to a regenerative and restorative economy. The vision of the Alliance is to facilitate the development of a **net zero supply chain for pharmaceutical products**, which will necessitate a collective effort. The Alliance will involve, connect and coordinate suppliers, pharmaceutical companies, manufacturers and service providers along the supply chain of pharmaceutical products. The Alliance is a working group, with commonly shared goals towards net zero GHG emissions, engages collaboration with academia and non-profit organisations as well as sponsors projects with the joint aims.

## Our Mission

The Alliance seeks to **accelerate the transition of pharmaceutical products towards net zero** across the spaces of business, regulation and academia. This goal shall be reached by implementing regenerative and restorative practices based on GHG emissions reduction and the Circular Economy principles promoted by the Ellen MacArthur Foundation. We believe the answers will come as we transition our business from a linear mindset of 'take-make-dispose' to a low GHG emissions and circular mindset.

The Alliance focuses on three interlinking areas:

- **Business partnership**

Business innovation sits at the heart of economic transitions, thus interdisciplinary, project-based and participatory approaches shall be emphasized in order to achieve the Alliance's goals. Members shall share their best practices, standards, guidelines and learning experiences with other participants and share their learning among their own network.

- **Regulatory framework**

By engaging in political dialogue, the Alliance helps shape an appropriate regulatory framework for combined products, with the ultimate goal of reducing time to market, improving access to innovative products and better responding to patients' needs.

- **Academic learning**

The Alliance fosters learning and knowledge exchange, in particular learning about the low-emissions and circular economy, and the systems thinking required to accelerate the transition.

## Our core values

The Alliance members shall be committed to the following values, which enable open-minded collaboration:

- **Inclusive collaboration**

We intend to work together along the product supply chain for pharmaceutical products to reach this objective, including all relevant public and private actors globally, whilst ensuring the functionalities of pharmaceutical products and packaging and not compromising on product safety, efficacy or security.

- **Science-based approach**

We work in interdisciplinary projects following a science-based approach and the most common standards. The jointly developed targets shall be mandatory and specified to all the Alliance partners. Measurable key performance indicators help us maintain the focus on our vision.

- **Systemic initiatives**

The Alliance brings together organisations and other actors such as public institutions and non-profit organisations from across supply chains to tackle systemic stalemates that organisations cannot overcome in isolation. The Alliance takes a global, cross-organisational approach to material flow, enabling global systemic thinking. The Alliance is committed to open collaboration with existing initiatives, standards and principles to leverage existing work and advance business transformation towards net zero.

- **Transparency and accountability**

The Alliance engages in public reporting and disclosure on its progress to key internal and external stakeholders, including investors, customers, consumers and, where

required, regulators, sharing information on good practices with all stakeholders in order to reach the goals of the Alliance.

## Our Targets

In order to act towards the **goal of net zero**, members of the Alliance are striving for the following targets:

- **Short-term (by the end of 2023)**

We raise awareness and create a strong partnership in the industry. Specific programmes to reduce and offset GHG emissions including waste reduction in pharmaceutical products have been established within our companies. The full supply chain of pharmaceutical products is represented by the Alliance.

- **Mid-term (by the end of 2026)**

Business models have been developed collaboratively based on GHG emissions reduction and Circular Economy principles. We have established transparent key performance indicators for comparing GHG emissions reduction across the industry. We have developed a net zero product offering within the Alliance.

- **Long-term (by the end of 2030)**

Our company operations covering the supply chain of the net zero product offering will be net zero or show significant GHG emissions reduction. We have enabled the launch of net zero pharmaceutical products in regulated markets. As per a third-party audit, the overall supply chain is confirmed net zero.

## Signatories

We the signatories commit to work together, each within our own competencies and responsibilities, to deliver the contents of this Manifesto.

